Quarterly ResultMay 7, 2026, 07:07 AM
Insmed Q1 Revenue $306.0M; BRINSUPRI Revenue +44% to $207.9M
AI Summary
Insmed Incorporated reported strong financial results for the first quarter ended March 31, 2026, with total company revenues reaching $306.0 million. BRINSUPRI revenues surged 44% sequentially to $207.9 million, while ARIKAYCE revenues grew 6% year-over-year to $98.1 million. The company also announced positive topline results from the Phase 3b ENCORE study for ARIKAYCE and the initiation of the Phase 3 PALM-PAH study for TPIP, while reiterating its full-year 2026 revenue guidance for both key products.
Key Highlights
- Total Company Revenues were $306.0 million for Q1 2026.
- BRINSUPRI revenues grew 44% over Q4 2025 to $207.9 million.
- ARIKAYCE revenues grew 6% over Q1 2025 to $98.1 million.
- Net loss was $163.6 million, or $0.76 per share, compared to $256.6 million, or $1.42 per share in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled approximately $1.2 billion as of March 31, 2026.
- Company reiterated 2026 BRINSUPRI revenue guidance of at least $1 billion.
- Company reiterated 2026 ARIKAYCE revenue guidance of $450 million to $470 million.
- Phase 3b ENCORE study of ARIKAYCE met primary and all multiplicity-controlled secondary culture conversion endpoints.
- Phase 3 PALM-PAH study of TPIP in patients with PAH was initiated in April 2026.
Price Impact
More from INSM